Transparency
Market Research (TMR) has published a new report titled, “Recombinant Plasma
Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast, 2018–2026”. According to the report, the global recombinant
plasma protein therapeutics market was
valued at US$ 8.2 Bn in 2017. It is anticipated expand at a CAGR of 8.6% from
2018 to 2026. Replacement of plasma derived proteins by recombinant plasma
products, increase in the number of products launched, and rise in the demand
for novel therapies of hemophilia treatment are anticipated to drive the
market.
Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=62010
Rising Number
of Regulatory Approvals to Drive Market
There has been an increase in the
number of regulatory approvals in the last three years that have increased the
availability of various options for patients with rare diseases such as
hemophilia and other bleeding disorders. These approvals enabled companies to
expand their product portfolios and gain competitive advantage. For instance,
in September 2017, Ministry of Health, Labour and Welfare, Japan, approved CSL
Behrings AFSTYLA, a recombinant factor VIII indicated for the treatment of
hemophilia A. AFSTYLA has been also approved in the U.S., Canada, and
Switzerland. In April 2018, Shire received Food and Drug Administration (FDA)
approval for VONVENDI recombinant von Willebrand factor, indicated for
perioperative management of bleeding in patients with von Willebrand disease
(VWD). In July 2018, Bayer AG announced the approval for Kovaltry, recombinant
factor VIII from the regulatory authorities in China, indicated for the
treatment of hemophilia A.
Asia Pacific
offering Numerous Growth Opportunities to the Market
In Asia Pacific, increase in the
number of cases of rare hematology disorders, rise in adoption of recombinant
DNA technology for therapeutic use, and surge in R&D expenditure by
pharmaceutical & biotechnology companies are anticipated to drive the
market. Additionally, the demand for third-generation recombinant coagulation
factors is increasing in Japan and China, which further creates growth
opportunities in the market. Government and non-government organizations are
presently taking efforts to increase awareness about hemophilia A and
hemophilia B, helping the general population to understand the cases,
diagnosis, and treatment methods for such rare diseases. Countries such as
China, Japan, Australia, and New Zealand are currently switching to recombinant
plasma therapies as standard for hemophilia A treatment, with regulatory
authorities. According to Hemophilia Foundation Australia, 80% of patients with
bleeding disorders are treated with recombinant coagulation factors. Therefore,
increase in the use of recombinant therapies for hemophilia treatment is
expected to drive the market during the forecast period.
Strategic
Approaches and Increasing Focus on R&D by Market Players
The report also provides profiles
of leading players operating in the global recombinant plasma protein
therapeutics market. These include CSL Limited, Shire (Takeda Pharmaceutical
Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ
Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer
Inc.
New product launch, acquisition,
geographical expansion, collaborations, and distribution agreements enable
these companies to expand their presence in the global market. In January 2019,
Shire was acquired by Takeda Pharmaceutical Company Limited, a pharmaceutical
company based in Japan. With this acquisition, Takeda Pharmaceutical Company
Limited is expected to strengthen its geographical presence. In January 2018,
Sanofi, a leading pharmaceutical company, acquired Bioverativ Therapeutics
Inc., which operated as a part of Sanofi Genzyme. Other market players have
also undertaken numerous initiatives to expand their business in emerging
markets. Leading market players are also focusing on increasing their customer
base in countries in Asia Pacific such as China, Japan, and Australia. Market
players are also supporting several campaigns for increasing awareness about
hematological disorders and availability of treatment options such as
recombinant plasma proteins and the advantages offered by these products.
More Trending
Reports by Transparency Market Research:
About Us
Transparency Market Research is a
global market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision
makers. Our experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather, and
analyze information.
Our data repository is
continuously updated and revised by a team of research experts, so that it
always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
